ArticleScientific reports2019
Unveil the Anticancer Potential of Limomene Based Therapeutic Deep Eutectic Solvents.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 104 citations in OpenAlex.
- Toxicity Assessment and Bioremediation of Deep Eutectic Solvents by Haloferax mediterranei: A Step toward Sustainable Circular Chemistry.ChemSusChem · 2025Article
- Exploring Ibuprofen-Menthol Eutectic Systems: Physicochemical Properties and Cytotoxicity for Pharmaceutical Applications.Pharmaceutics · 2025Article
- Natural deep eutectic solvents (NaDES): green solvents for pharmaceutical applications and beyond.Green chemistry : an international journal and green chemistry resource : GC · 2025Review
- An Overview on the Role of Ionic Liquids and Deep Eutectic Solvents in Oral Pharmaceuticals.Pharmaceutics · 2025Review
- Enhanced Extraction and Separation with HPLC-DAD of Phenolic and Flavonoid Antioxidants fromAntioxidants (Basel, Switzerland) · 2025Article
- Deep eutectic solvent enhances antibacterial activity of a modular lytic enzyme against Acinetobacter baumannii.Scientific reports · 2025Article
- Exploring Deep Eutectic Solvents as Pharmaceutical Excipients: Enhancing the Solubility of Ibuprofen and Mefenamic Acid.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Pharmaceutical applications of therapeutic deep eutectic systems (THEDES) in maximising drug delivery.Heliyon · 2024Review
- Using Natural Deep Eutectic Systems as Alternative Media for Ocular Applications.Pharmaceutics · 2023Article
- Deep Eutectic Solvents Comprising Organic Acids and Their Application in (Bio)Medicine.International journal of molecular sciences · 2023Review
- Review
- Controversy on the toxic nature of deep eutectic solvents and their potential contribution to environmental pollution.Heliyon · 2022Review
- Therapeutic deep eutectic solvent-based microemulsion enhances anti-inflammatory efficacy of curcuminoids and aromatic-turmerone extracted fromRSC advances · 2022Article
- Article
- Therapeutic Deep Eutectic Systems towards the Treatment of Tuberculosis and Colorectal Cancer: Opportunities and Challenges.Molecules (Basel, Switzerland) · 2021Review
- Therapeutic Liquid Formulations Based on Low Transition Temperature Mixtures for the Incorporation of Anti-Inflammatory Drugs.Pharmaceutics · 2021Article
- Selected Monocyclic Monoterpenes and Their Derivatives as Effective Anticancer Therapeutic Agents.International journal of molecular sciences · 2021Review
- Deep Eutectic Solvents as Active Pharmaceutical Ingredient Delivery Systems in the Treatment of Metabolic Related Diseases.Frontiers in pharmacology · 2021Review
- Optimal Design of THEDES Based on Perillyl Alcohol and Ibuprofen.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Deep eutectic solvents have been recently reported as an interesting alternative to improve the therapeutic efficacy of conventional drugs, hence called therapeutic deep eutectic solvents (THEDES). The main objective of this work was to evaluate the potential of limonene (LIM) based THEDES as new possible systems for cancer treatment. LIM is known to have antitumor activity, however it is highly toxic and cell viability is often compromised, thus this compound is not selective towards cancer cells. Different THEDES based on LIM were developed to unravel the anticancer potential of such systems. THEDES were prepared by gently mixing saturated fatty acids menthol or ibuprofen (IBU) with LIM. Successful THEDES were obtained for Menthol:LIM (1:1), CA:LIM (1:1), IBU:LIM (1:4) and IBU:LIM(1:8). The results indicate that all the THEDES present antiproliferative properties, but IBU:LIM (1:4) was the only formulation able to inhibit HT29 proliferation without comprising cell viability. Therefore, IBU:LIM (1:4) was the formulation selected for further assessment of anticancer properties. The results suggest that the mechanism of action of LIM:IBU (1:4) is different from isolated IBU and LIM, which suggest the synergetic effect of DES. In this work, we unravel a methodology to tune the selectivity of LIM towards HT29 cell line without compromising cell viability of healthy cells. We demonstrate furthermore that coupling LIM with IBU leads also to an enhancement of the anti-inflammatory activity of IBU, which may be important in anti-cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.